Birgit Grünberger
YOU?
Author Swipe
View article: New Perspectives in the Management of Triple-Negative Breast Cancer
New Perspectives in the Management of Triple-Negative Breast Cancer Open
Background: The biological heterogeneity of triple-negative breast cancer (TNBC) and the availability of a growing number of therapeutic options necessitate continuous redefinition of the ideal treatment algorithm for patients with TNBC. A…
View article: Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer
Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer Open
Summary Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have transformed the treatment of hormone-receptor-positive, human epidermal growth factor receptor 2‑negative (HR+/HER2−) breast cancer, becoming the standard in first-line endocrin…
View article: Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer
Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer Open
This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian, and Swiss Onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoad…
View article: Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy – An Update
Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy – An Update Open
Over the last decade, therapeutic options for patients with gastric cancer have improved significantly. However, despite these recent advances, mortality is still substantial. Surgery and chemotherapy represent the cornerstones of patient …
View article: Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update Open
Summary In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2 positive breast cancer were published. To bring this new evidence into a clinical perspective, a group of Austrian breast cancer specialis…
View article: Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study
Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study Open
Aflibercept plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer after the failure of oxaliplatin-containing therapy. QoLiTrap prospectively evaluated the quality of life (QoL) and effectiveness of this…
View article: Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine
Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine Open
Background: The management of patients with metastatic pancreatic cancer (mPC) is challenging, and the optimal treatment strategy is debated among experts. In an attempt to identify treatment decision criteria and to investigate variations…
View article: Supplementary Material for: Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer
Supplementary Material for: Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer Open
Background: Neoadjuvant chemotherapy with methotrexate-vinblastine-doxorubicin-cisplatin (MVAC) is the standard of care for muscle-invasive urothelial bladder cancer. Gemcitabine plus cisplatin (GC) shows similar efficacy with less toxicit…